Clinical Trial Innovation: A Year in Review and What’s to Come in 2019
2018 has been an exciting year in the clinical trials industry, as we have seen many changes in novel concepts, and the evolution of some concepts to the point where initiatives and pilots are crystalizing into common practice.
2018 has been an exciting year in the clinical trials industry, as we have seen many changes in novel concepts, and the evolution of some concepts to the point where initiatives and pilots are crystalizing into common practice. The biopharmaceutical industry is enthusiastic about defining and solidifying the new concept of patient connectivity and information exchange, whereas digital health and AI concepts are implementedin many different forms. Alternatively, the well-established field of quality, risk management, and vendor oversight dabbles cautiously into analytics and innovation.
The Evolution of Patient Information Exchange and Connectivity
The concept of patient information exchange (also known as patient connectivity) emerged recently and had seen rapid evolution. At the beginning of 2018, while many biopharmaceutical executives have been talking about the theory,
Additionally, information exchange envelops study site feedback to improve the patient experience in clinical trials. Near the end of 2018,
Moreover, Janssen is focusing on establishing relationships through patient community outreach, and supporting study sites with tools, information, and resources (driven by behavioral science) to assist patients through the clinical trial journey. Janssen is also embracing social media to attract patients to studies. On the other hand, BMS is taking a different approach by leveraging internet technology to maintain patient engagement with BMS studies; definitively, BMS’s Study Connect program screens, refers and educates patients about clinical trials, and if a patient disqualifies, continues to engage them. It is clear that the realm of patient connectivity is broad, and the biopharmaceutical industry is tackling critical pain points first (i.e., recruitment and engagement); it is likely that we will see initiatives that give data back to patients in the future.
Digital Health is Gaining Ground
The vast domain of digital health includes many factions ranging from wearable devices to digital biomarkers, to remote clinical trials. Experts have indicated that the industry has a
Blockchain and AI
While blockchain is commonplace in technology, cryptocurrency, and
Risk Management and Vendor Oversight
Quality management analytics have penetrated many areas in industry-based clinical trials, and are now starting to impact regulatory agencies.
RBM practices are starting to scale in the industry, as several large biopharmaceutical enterprises have completed RBM pilots, adjusted their functions and roles, and are starting to ramp RBM activities on many studies.
What’s to Come in 2019?
On the patient information exchange and connectivity front, we expect to see more biopharmaceutical companies targeting main pain points (i.e., recruitment, enrollment, and retention). In the next year, it is not likely that we will see clinical trial data exchange with patients post-study completion; however, this initiative will eventually be tackled. On the digital health front, we expect to see much advancement with new measures and validations using eDROs. On the blockchain and AI front, it is unlikely that we’ll see any blockchain pilots. Though, we expect more AI-based technologies to emerge and grow. In the risk management and oversight topic, we anticipate seeing more novel quality management concepts emerge to demonstrate alignment with ICH E6 R2, and see technology growth, as the guidance hints that technology usage is required to properly demonstrate adequate quality and risk management.
Moe Alsumidaie, MBA, MSF is Chief Data Scientist at Annex Clinical, and Editorial Advisory Board member for and regular contributor to Applied Clinical Trials.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025